Merck Pays $6.7B for Terns Acquisition to Boost TERN-701 Pipeline
Merck will acquire Terns Pharmaceutical for $6.7 billion to strengthen its cancer pipeline with TERN-701, marking the third multi-billion-dollar deal in the past year. The company projects a over $70 billion mid-2030s commercial opportunity, maintains a 73% gross margin and has raised dividends for 14 consecutive years.
1. Merck Acquires Terns for $6.7 Billion
Merck has agreed to purchase Terns Pharmaceutical for $6.7 billion, marking its third acquisition exceeding $2 billion in the past year. This move secures rights to TERN-701, an oral BCR-ABL1 inhibitor targeting chronic myeloid leukemia, as Merck seeks to deepen its oncology offerings.
2. Strengthening Cancer Pipeline with TERN-701
TERN-701 adds to Merck’s pipeline of targeted therapies and is positioned to address resistance in chronic myeloid leukemia patients. The acquisition underscores Merck’s focus on high-growth oncology assets to drive long-term clinical and commercial value.
3. Financial Outlook and Dividend Track Record
Merck forecasts over $70 billion in commercial opportunity by the mid-2030s and sustains a 73% gross margin. The company has boosted its dividend for 14 straight years, reinforcing its commitment to shareholder returns amid an aggressive M&A strategy.